Craniospinal irradiation(CSI) in patients with leptomeningeal metastases: risk-benefit-profile and development of a prognostic score for decision making in the palliative setting
Open Access
- 1 June 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in BMC Cancer
- Vol. 20 (1), 1-10
- https://doi.org/10.1186/s12885-020-06984-1
Abstract
The aim of our study was to assess the feasibility and oncologic outcomes in patients treated with spinal (SI) or craniospinal irradiation (CSI) in patients with leptomeningeal metastases (LM) and to suggest a prognostic score as to which patients are most likely to benefit from this treatment. Nineteen patients treated with CSI at our institution were eligible for the study. Demographic data, primary tumor characteristics, outcome and toxicity were assessed retrospectively. The extent of extra-CNS disease was defined by staging CT-scans before the initiation of CSI. Based on outcome parameters a prognostic score was developed for stratification based on patient performance status and tumor staging. Median follow-up and overall survival (OS) for the whole group was 3.4 months (range 0.5–61.5 months). The median overall survival (OS) for patients with LM from breast cancer was 4.7 months and from NSCLC 3.3 months. The median OS was 7.3 months, 3.3 months and 1.5 months for patients with 0, 1 and 2 risk factors according to the proposed prognostic score (KPS < 70 and the presence of extra-CNS disease) respectively. Nonhematologic toxicities were mild. CSI demonstrated clinically meaningful survival that is comparable to the reported outcome of intrathecal chemotherapy. A simple scoring system could be used to better select patients for treatment with CSI in this palliative setting. In our opinion, the feasibility of performing CSI with modern radiotherapy techniques with better sparing of healthy tissue gives a further rationale for its use also in the palliative setting.Keywords
This publication has 24 references indexed in Scilit:
- Optimal Normal Tissue Sparing in Craniospinal Axis Irradiation Using IMRT With Daily Intrafractionally Modulated Junction(s)International Journal of Radiation Oncology*Biology*Physics, 2011
- Prognostic factors and treatment options in patients with leptomeningeal metastases of different primary tumors: a retrospective analysisZeitschrift für Krebsforschung und Klinische Onkologie, 2010
- Intensity-Modulated Radiotherapy for Craniospinal Irradiation: Target Volume Considerations, Dose Constraints, and Competing RisksInternational Journal of Radiation Oncology*Biology*Physics, 2007
- Capecitabine Therapy of Central Nervous System Metastases from Breast CancerJournal of Neuro-Oncology, 2007
- Breast cancer leptomeningeal metastasis—the role of multimodality treatmentJournal of Neuro-Oncology, 2007
- Long-Term Clinical Response in Leptomeningeal Metastases from Breast Cancer Treated with Capecitabine Monotherapy: A Case ReportClinical Breast Cancer, 2006
- Neoplastic MeningitisJournal of Clinical Oncology, 2005
- The relevance of intraventricular chemotherapy for leptomeningeal metastasis in breast cancer: a randomised studyEuropean Journal of Cancer, 2004
- Leptomeningeal metastasis: survival and prognostic factors in 155 patientsJournal of the Neurological Sciences, 2004
- Durable response of breast cancer leptomeningeal metastasis to capecitabine monotherapyNeuro-Oncology, 2004